Monoclonal Antibody Collaboration and Licensing Deals 2019-2024

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2019
•    Browse monoclonal antibody collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates

Chapter 3 – Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 – Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles

Chapter 5 – Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 – Monoclonal antibody dealmaking by technology type

Deal directory

Deal directory – Monoclonal antibody deals by company A-Z
Deal directory – Monoclonal antibody deals by deal type
Deal directory – Monoclonal antibody deals by therapy area

Deal type definitions

About Biopharma Research Ltd  
Current Partnering
Current Agreements
Recent report titles from Current Partnering

 
Table of figures

Figure 1: Monoclonal antibody deals since 2016
Figure 2: Active monoclonal antibody dealmaking activity – 2016 - 2024
Figure 3: Monoclonal antibody deals by deal type since 2016
Figure 4: Monoclonal antibody deals by therapy area since 2016
Figure 5: Monoclonal antibody deals by industry sector since 2016
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2016
Figure 11: Most active monoclonal antibody dealmakers 2016 - 2024
Figure 12: Monoclonal antibody deals by technology type since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

1ST Biotherapeutics, 3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4D Pharma, 9 Meters Biopharma, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, Abbvie, AbCellera Biologics, Abdul Latif Jameel Health, ABL Bio, Ablexis, Aboundbio, Ab Studio, AbTherx, Abveris, Abzena, AcedrA BioPharmaceuticals, Acerta Pharma, AchilleS Vaccines, Adagene, Adimab, Adlai Nortye, Advanz Pharma, Advaxis, Aegis Life, Aevi Genomic Medicine, AffaMed Therapeutics, AGC Biologics, Agenus Bio, Agilent Technologies, AgomAb Therapeutics, AimedBio, AIM ImmunoTech, Aimmune Therapeutics, Ajinomoto, Akeso Biopharma, Akston Biosciences, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Alkyon Therapeutics, Alligator Bioscience, Allinaire Therapeutic, Alloy Therapeutics, Almac Group, Almirall, Alphamab Biopharmaceuticals, Alpine Immune Sciences, Alvotech, ALX Oncology, Alzheimer's Drug Discovery Foundation, Amgen, Amneal Pharmaceuticals, Amolyt Pharma, Amplyx Pharmaceuticals, Angios, Ankyra Therapeutics, Antengene, Antidote Therapeutics, Apeiron Biologics, Apexigen, Apollo Therapeutics, Applied BioMath, APRINOIA Therapeutics, Aptevo Therapeutics, Arch Oncology, Arcus Biosciences, argenx, Aridis Pharmaceuticals, Arovella Therapeutics, Ascentage Pharma, Asher Biotherapeutics, Asieris MediTech, Aslan Pharma, ASLAN Pharmaceuticals, Astellas Pharma, AstraZeneca, Astria Therapeutics, Atlante Biotech, Atlas Antibodies, Atreca, ATUM, Augmenta, Avalo Therapeutics, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Axantia, Banner Alzheimer's Institute, Basilea Pharmaceutica, Bausch & Lomb, Bayer, Beckman Coulter, BeiGene, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, Betta Pharmaceuticals, Bill and Melinda Gates Foundation, Bio-Manguinhos/Fiocruz, Bio-Thera Solutions, BioArctic AB, BioAtla, BioCity Biopharma, Biocon, Biocytogen, Bioelectronica, Bioeq IP, Biogen, BioInvent, Biomedical Advanced Research and Development Authority, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, Bionoveo, BioNTech, BiosanaPharma, Biosion, Biotheus, Biotools, BioXcel, BJ Bioscience, Blackstone, Bluebird Bio, BlueJay Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boston Immune Technologies and Therapeutics, Bpifrance, BridgeBio Pharma, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, C-Bridge Capital, Calypso Biotech, CanariaBio, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research UK, Cancer Science Institute of Singapore, CanCure, Care Access Research, Caris Life Sciences, CARsgen, Cartexell, CASI Pharmaceuticals, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Cellectis, Celltrion, Celsius Therapeutics, Celularity, Cend Therapeutics, Cessation Therapeutics, CG Oncology, Champions Oncology, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Chiesi Farmaceutici, Chime Biologics, China Resources Pharmaceutical Commercial Group International Trading, Chiome Bioscience, Cipla, Circio, City of Hope Comprehensive Cancer Center, Clinical Trial and Consulting Services, Clinica Universidad Navarra, CMAB Biopharma, Coherus Biosciences, Compass Therapeutics, Compugen, Convergent Therapeutics, Creative Biolabs, Cromos Pharma, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cue Biopharma, Curative Biotechnology, Cure Duchenne, CureVac, Curia, Curis, Cytea Bio, Cytodyn, Cytovation, Daiichi Sankyo, Defense Advanced Research Projects Agency, Department of Defense, Dermira, Disc Medicine, Dong-A ST, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Duke University, Duoning Biotechnology, E25Bio, EirGenix, Eisai, Elanco, Elektrofi, Elevar Therapeutics, Elevation Oncology, Elicio Therapeutics, Eli Lilly, Emergent BioSolutions, Enlivex, Entos Pharmaceuticals, Enzene Biosciences, Enzolytics, EQRx, Equillium, Erasca, Erasmus University Medical Center, EsoCap, Eucure Biopharma, European Union Regional Development Fund, EUSA Pharma, Evaxion Biotech, Everest Medicines, Eversana, Evopoint Biosciences, Evotec, Excellmab, Exelixis, F-Star Therapeutics, FairJourney Biologics, FatiAbGen, Ferring Pharmaceuticals, Five Prime Therapeutics, FLX Bio, Formosa Pharmaceuticals, Forty Seven, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundery Innovations, French National Blood Service, Frontage Clinical Services, Fuji Pharma, Fujirebio Diagnostics, Fusion Pharmaceuticals, FutureGen Biopharm, Galecto, GC Cell, Gedeon Richter, Genagon Therapeutics, Genentech, Generation Biotech, GenFleet Therapeutics, Genmab, Gennao Bio, Genome and Company, Genprex, GenScript Biotech, GenScript ProBio, Georgetown University, GI Innovation, Gilead Sciences, Goldfinch Bio, Gossamer Bio, GO Therapeutics, GSK, Halozyme Therapeutics, Harbour Antibodies, Harbour Biomed, Henlius Biotech, HiberCell, HIBio, HiFiBio, Highlight Therapeutics, High Line Bio, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Therapeutics, Huadong Medicine, Hualan Genetic, Humanigen, Hummingbird Bioscience, Huyabio International, Hypospray Pharma, I-mab, iBio, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, IDBiologics, IDEAYA Biosciences, Igyxos, ImCheck Therapeutics, IMIDomics, Immatics Biotechnologies, Immix Biopharma, Immune-Onc Therapeutics, ImmuneCyte Life Sciences, ImmuneOncia Therapeutics, Immunitas Therapeutics, Immunocore, Immunome, Immunomedics, ImmunoPrecise Antibodies, Immutep, Imugene, IMV, Incyte, Indaptus Therapeutics, Indiana University, Indian Institute of Science Education and Research, Infex Therapeutics, InflamaCORE, InflaRx, Inhalon Biopharma, Initium Therapeutics, Innovent Biologics, Inovio, InSilicoTrials, Inspirna, Institut Bergonie, Institute for Basic Science, Intas Pharmaceuticals, Integral Molecular, INTELLiSTEM, Intensity Therapeutics, IntoCell, Intract Pharma, Invetx, InxMed, IO Biotech, Ionova, IONTAS, Ipsen, IRBM, Italian Association for the Study of Pancreas, iTeos Therapeutics, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Research & Development, Jasper Therapeutics, Jazz Pharmaceuticals, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Junshi Biosciences, Just Biotherapeutics, Juvenile Diabetes Research Foundation, KAHR Medical, Kalbe Genexine Biologics, KangaBio, KBI BioPharma, KBio, Kennedy Institute of Rheumatology, Kiadis Pharma, Kindred Bio, Kineta, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kleo Pharmaceuticals, KPM Tech, Kyowa Hakko Kirin, Kyttaro, Laekna, Lassen Therapeutics, Lava Therapeutics, LEO Pharma, Leukemia & Lymphoma Society, LifeMax Laboratories, Ligand Pharmaceuticals, Linnaeus Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lobesity Pharma, Lonza, Lunit, Lupus Therapeutics, Lyvgen Biopharma, MAB Discovery, MAbSilico, mAbsolve, mAbXience, Mabylon, Macrogenics, MAIA Biotechnology, Manhattan BioSolutions, Mapp Biopharmaceutical, Massachusetts General Hospital, Matrix Medical Network, Mayo Clinic, McLean Hospital, MD Anderson Cancer Center, Medical Research Council, Medicenna Therapeutics, MediLink Therapeutics, Medimabs, Medison Pharma, Meiji Seika, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merus, Microbiotica, Mitsubishi Tanabe Pharma, Molcure, Monopar Therapeutics, MoonLake Immunotherapeutics, MorphoSys, Mount Sinai Health System, MSD, MS Pharma, Mundipharma, Mustang Bio, myTomorrows, Nanjing Leads Biolabs, Nantes University, Nascent Biotech, National Cancer Institute, National Comprehensive Cancer Network (NCCN), National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse (NIDA), National Institutes of Health, National University Cancer Institute, Navrogen, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoImmuneTech, Neoleukin Therapeutics, Neotope, NETRIS Pharma, Neuraxpharm, Neurimmune Therapeutics, Neximmune, NGM Biopharmaceuticals, NiKang Therapeutics, Nkarta Therapeutics, NKGen Biotech, NKMax America, Nona Biosciences, Nordic Society of Gynaecological Oncology, NorthStar Medical Radioisotopes, Nouscom, NovalGen, Novartis, Novelty Nobility, Novocure, Novo Nordisk, Noxopharm, Numab, Nykode Therapeutics, OBI Pharma, Olatec Therapeutics, Olivia Newton-John Cancer Research Institute, Ology Bioservices, Omeros, OncoC4, Oncologie, Oncolytics Biotech, OncoResponse, OncoSec Medical, OncoVent, OncoVerity, Oncternal Therapeutics, OncXerna Therapeutics, Ono Pharmaceutical, Ordaos Bio, Orient EuroPharma, OSE Immunotherapeutics, Oxford BioTherapeutics, Pandion Therapeutics, Parexel Biotech, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, PharmaEssentia, Pharmapark, PhaseBio Pharmaceuticals, Pieris Pharmaceuticals, Pierre Fabre, Pionyr Immunotherapeutics, PlantForm, PlantPraxis Biotecnologia, PMV Pharma, Pneuma Respiratory, POINT Biopharma, Polpharma, Portage Biotech, Precision BioSciences, Prellis Biologics, Prelude Therapeutics, Prestige BioPharma, Progenetics, Promega, Prothena, Provention Bio, PT Etana Biotechnologies, Purdue University, PureTech Health, Pyxis Oncology, Q32 Bio, QBiotics, QIAGEN, Quantum Leap Health Care Collaborative, Qurient, R-Pharm, Rallybio, Rani Therapeutics, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regnum, Releviate Therapeutics, RemeGen, Roche, Rockefeller University, Rocket Pharmaceuticals, Roivant Sciences, Roswell Park Cancer Institute, RQ Biotechnology, RubrYc Therapeutics, Rxilient Biotech, Rznomics, SAB Biotherapeutics, Saccharo, Saga University, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanofi, Sanofi US Services, Sanyou Biopharmaceuticals, SaudiVax, Scandion Oncology, SciClone Pharmaceuticals, SciNeuro Pharmaceuticals, Seagen, Seattle Genetics, Seismic Bio, Seismic Therapeutic, Selecxine, Selexis, Sensei Biotherapeutics, SERB Pharmaceuticals, Serum Institute of India, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, Sharp HealthCare, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Shionogi, SHL Medical, SIGA Technologies, Simcere Pharmaceuticals, Simcha Therapeutics, Sirnaomics, Sonnet BioTherapeutics, Sorrento Therapeutics, SOTIO, Spanish National Research Council, Specialised Therapeutics, SpikImm, STADA Arzneimittel, Strata Oncology, Sud Investments, Surface Oncology, Suzhou Connect Biopharmaceuticals, Syndax Pharmaceuticals, Syngene International, Synlogic, Syracuse University, Syros Pharmaceuticals, T-Cure Bioscience, Taiho, TaiMed, Takeda Pharmaceutical, Talem Therapeutics, Tavotek Biotherapeutics, TCR2 Therapeutics, Telcon RF Pharmaceuticals, Telix Pharmaceuticals, Tempest Therapeutics, Teon Therapeutics, Tessa Therapeutics, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TFF Pharmaceuticals, TG Therapeutics, Tharimmune, The International AIDS Vaccine Initiative, The Jackson Laboratory, Theramex, Thermo Fisher Scientific, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, TNAX Biopharma, TONIX Pharmaceuticals, Toregem BioPharma, Torque Therapeutics, TRACON Pharmaceuticals, Transcenta, TransThera, TrialSpark, Trianni, Trinomab Biotech, Trio Pharmaceuticals, Triumvira Immunologics, TSB Therapeutics, Tsinghua University, Turgut Ilaclari, Twist Bioscience, UbiVac, UCB, Ultragenyx Pharmaceuticals, UnitedHealth, University of Birmingham, University of California Los Angeles, University of California Riverside, University of Florida, University of Oxford, University of Pennsylvania, University of Washington, Upadia, UroGen Pharma, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, Utrecht University, Vaccinex, ValenzaBio, Vanderbilt University, Vcell Healthcare, Velabs Therapeutics, Verseau Therapeutics, Vetter, Viela Bio, Vir Biotechnology, Viroclinics Biosciences, Vyera Pharmaceuticals, Wellmarker Bio, Werewolf Therapeutics, WindMIL Therapeutics, Wistar Institute, WuXi Biologics, Wuxi Shuangliang Biotechnology, Xbrane Bioscience, Xencor, XERIS Pharmaceuticals, Xilio Therapeutics, Xoma, Xuanzhu Biopharma, Xyphos Biosciences, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yas Holding, ZabBio, ZAI Laboratory, Zenas BioPharma, Zenyaku Kogyo, Zumutor Biologics, Zura Bio, Zydus Cadila, Zymedi, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.